Protein Design's Crohn's Treatment Shown Safe

Publish date:

Protein Design Labs

(PDLI) - Get Report

said its new treatment for Crohn's disease was well tolerated in a safety trial.

The Fremont, Calif., biotech company said the Phase I/II trial on its Smart Anti-Gamma interferon antibody support moving the treatment to the next phase of clinical development.

The shares were recently up 3.25% to $35.92.